Axsome Therapeutics Inc. (AXSM) had a good day on the market for Tuesday October 15 as shares jumped 13.1% to close at $20.63. About 1.43 million shares traded hands on 10,233 trades for the day, compared with an average daily volume of n/a shares out of a total float of 34.42 million. After opening the trading day at $18.65, shares of Axsome Therapeutics Inc. stayed within a range of $21.30 to $18.60.
With today’s gains, Axsome Therapeutics Inc. now has a market cap of $710.05 million. Shares of Axsome Therapeutics Inc. have been trading within a range of $30.50 and $1.94 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer’s. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer’s disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
Axsome Therapeutics Inc. is based out of New York, NY and has some 37 employees. Its CEO is Herriot Tabuteau.
Axsome Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.